🟢 Adaptive Biotechnologies is trading 4.3% up today after BTIG raised its price target to $34

Adaptive Biotechnologies is trading 4.3% up at $29.07 after BTIG raised its price target to $34 from $25 and maintained a Buy rating on September 22. - BTIG cited the company’s clonoSEQ assay and expanded NCCN multiple-myeloma MRD-testing guidance. - Company-specific developments appear to be outweighing biotechnology-sector weakness and broader market pressure on September 24.